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More on Reports of Esophageal Cancer  
with Oral Bisphosphonate Use
To the Editor: In her letter to the editor, Wysow-
ski (Jan. 1 issue)1 notes that the Food and Drug 
Administration (FDA) received reports of 23 cases 
of esophageal cancer in patients who had re-
ceived oral bisphosphonates, and she calls for 
studies that investigate whether bisphosphonate 
use is associated with an increased risk of this 
cancer. The reported cases of esophageal cancer 
occurred after a relatively short duration of use, 
with a median time to diagnosis of 2.1 years.
Using data from national registers (1995 
through 2005), we individually matched 13,678 
patients with fracture who had filled more than 
one prescription for any oral bisphosphonate 
(62% for alendronate, 36% for etidronate, and 
2% for ibandronate, risedronate, or clodronate) 
with 27,356 patients with fracture who did not fill 
any bisphosphonate prescriptions and who were 
similar with respect to age (mean [±SD], 74.3±8.8 
years), sex (89.1% were women), and fracture type. 
We used a Cox proportional-hazards model that 
controlled for the Charlson index and the number 
of concomitant medications, incorporating the 
time to an event, death, or the end of the study. 
The study had a median follow-up time of 2.2 
years (mean, 2.8) and a median duration of expo-
sure to oral bisphosphonates of 1.5 years (mean, 
2.1). We identified 37 cases of esophageal cancer 
and 48 cases of gastric cancer over a period of 
128,300 patient-years. Patients receiving oral bis-
phosphonates were not at increased risk for esoph-
ageal cancer or gastric cancer (hazard ratio for 
the combined outcome, 0.78; 95% confidence in-
terval [CI], 0.49 to 1.26). The risk of esophageal 
cancer was significantly reduced (hazard ratio, 
0.35; 95% CI, 0.14 to 0.85; P = 0.02), whereas the 
risk of gastric cancer did not differ significantly 
from that among control subjects (hazard ratio, 
1.23; 95% CI, 0.68 to 2.22; P = 0.49).
Our study had several limitations. First, al-
though it was a large study, the cancer rates were 
low, so the confidence intervals were wide. Sec-
ond, oral bisphosphonates may have been targeted 
preferentially to and accepted by patients without 
upper gastrointestinal symptoms, leading to low 
risks. Third, the hazard ratios may have been 
overestimates, since the use of endoscopy is more 
likely in patients who receive oral bisphospho-
nates. Nonetheless, this national cohort study 
does not provide support for the suspected in-
crease in the risk of esophageal cancer early in 
the course of oral bisphosphonate therapy.
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To the Editor: Wysowski states that 23 cases of 
esophageal cancer among persons receiving oral 
bisphosphonates have been reported to the FDA 
since 1995. We compared the rates of esophageal 
cancer among persons receiving oral bisphospho-
nates with rates among persons receiving other 
osteoporosis medications (e.g., raloxifene or calci-
tonin) and with Surveillance, Epidemiology, and 
End Results (SEER) estimates.1 We searched the 
health care utilization records of Medicare bene-
ficiaries who were beginning treatment with an 
oral bisphosphonate or other osteoporosis medi-
cations in order to find a new diagnosis of esoph-
ageal cancer and treatments for esophageal cancer 
(i.e., chemotherapy, radiation therapy, or surgical 
procedures).
The rates of esophageal cancer are shown in 
Table 1. In standardized analyses, we found no 
increase in the incidence rate of esophageal can-
cer among persons who received oral bisphospho-
nates as compared with persons who received 
other osteoporosis medications and as compared 
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with SEER estimates. The rarity of esophageal 
cancer led to wide confidence intervals. However, 
the 95% confidence interval around the compari-
son with SEER incidence rates rules out a rate 
greater than 114.9 per 100,000 persons.
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To the Editor: With regard to Wysowski’s letter: 
the time from exposure to oral bisphosphonates 
to the diagnosis of esophageal cancer was brief, 
with a mean duration of 1 to 2 years, and for this 
reason we doubt that bisphosphonate use was 
the cause of esophageal adenocarcinoma. Rather, 
we suspect that in light of the high incidence of 
coexisting osteoporosis and Barrett’s esophagus 
among postmenopausal women, most women 
with esophageal adenocarcinoma had preexist-
ing, but undiagnosed, Barrett’s esophagus with 
dysplasia.
Lorenz C. Hofbauer, M.D. 
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To the Editor: With regard to the letter by 
Wysowski: we suggest that the time between ex-
posure to bisphosphonates and the diagnosis of 
esophageal cancer was too short to be compatible 
with a cause-and-effect relationship. Exposure to 
carcinogenic agents is measured in years before 
the development of a neoplasm. After it develops, 
a tumor may not be detected for years; for exam-
ple, a tumor requires 30 volume doublings to reach 
1 cm in diameter. Wysowski reports a time from 
exposure to diagnosis of 1.3 to 2.1 years. This 
duration results in a doubling time (16 to 26 days) 
that is incompatible with the natural history of 
esophageal cancer. Also, the author did not con-
trol for risk factors and did not assess the entire 
population at risk. Given the small number of 
cases reported, it is conceivable that the wide-
spread use of bisphosphonates could even have a 
protective value.
H. Ian Robins, M.D., Ph.D. 
Kyle D. Holen, M.D.
University of Wisconsin Paul P. Carbone  
 Comprehensive Cancer Center 
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To the Editor: The usefulness of Wysowski’s 
data is limited by the lack of a comparison group. 
Millions of people take bisphosphonates. World-
wide, esophageal cancer ranks fifth in the causes 
of death from cancer.1 By chance, some people 
with cancer will be bisphosphonate users. Are 23 
cases of cancer over a period of 13 years more 
than would be expected? Without controls, it is 
impossible to know.
Also, the data source is a voluntary-reporting 
database in which clinicians can report drugs as 
being a suspected cause of illness. Alendronate 
has long been known to cause esophagitis.2 Cli-
nicians observing esophageal cancer with bis-
phosphonate use might report it solely because 
of previous knowledge of this association with 
Table 1. Incidence Rates and Incidence-Rate Ratios for Esophageal Cancer.*
Group
Incidence Rate  
per 100,000 Persons
Incidence-Rate Ratio  
(95% CI)
Persons receiving oral bisphosphonates 26.7 —
Persons receiving other osteoporosis medications 48.4 0.55 (0.06–4.72)
Persons in the SEER registry 23.7 1.12 (0.26–4.84)
* Surveillance, Epidemiology, and End Results (SEER) results are for 5-year age strata in men and women 65 years of 
age or older. Incidence-rate ratios are for the comparison of persons who received oral bisphosphonates with persons 
who received other osteoporosis medications (raloxifene or calcitonin) and those in the SEER registry; thus, ratios be-
low 1.00 indicate a reduced risk among persons who received oral bisphosphonates. CI denotes confidence interval.
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esophagitis, resulting in a spurious association 
with cancer.
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To the Editor: Wysowski provides no informa-
tion on the expected rates of esophageal cancer 
among patients in the age group she studied, and 
she provides no data on known risk factors, ex-
cept for Barrett’s esophagus in one patient. The 
prevalence of chronic gastroesophageal reflux dis-
ease, a risk factor for esophageal cancer, is not 
known. Clearly, one cannot conclude on the basis 
of Wysowski’s letter that bisphosphonate use is 
associated with esophageal cancer.
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The author replies: The reports of esophageal 
cancer in users of oral bisphosphonates were 
voluntarily submitted to the FDA’s Adverse Event 
Reporting System, an early-warning system for 
reporting suspected drug reactions. A major limi-
tation of this system is underreporting; the extent 
of reporting is variable, but it is usually only about 
5 to 15%.1 Consequently, reliable incidence rates 
of esophageal cancer among users of oral bisphos-
phonates cannot be calculated from these reports 
and compared with U.S. cancer rates or those 
obtained from other sources.
Oral bisphosphonates might plausibly be as-
sociated with esophageal cancer, since they can 
cause erosive esophagitis,2 delayed healing, and 
persistent mucosal abnormalities.3 Multinucleated 
giant cells have been detected in esophageal in-
flammatory exudates.2 Whether these or other 
cells undergo malignant transformation is not 
known at this time, although Singh and Odze 
have suggested that changes in multinucleated 
giant cells in esophagitis “probably represent a 
regenerative response to injury.”4
Several correspondents state that the short 
duration of use of the drugs made the association 
improbable. However, not all patients’ use was 
short term, and if patients were at increased risk 
before bisphosphonate use, a long duration of 
exposure might not be required. Alternatively, 
short-term use of an oral bisphosphonate could 
lead to detection of a preexisting tumor.
Although there is uncertainty about whether 
the use of oral bisphosphonates increases the 
risk of esophageal cancer, it seemed prudent to 
disclose the reports, advise against the use of 
these drugs in patients with Barrett’s esophagus, 
and recommend definitive studies. Such studies 
should include a control group and be of suffi-
cient size, with a sufficient duration of exposure 
and follow-up and with analyses of confounding 
variables. Although the study by Abrahamsen et 
al. incorporated some of these criteria, insuffi-
cient data on long-term exposure and the lack of 
information on smoking status, alcohol use or 
nonuse, and body-mass index are limitations. The 
study by Solomon et al. cannot be properly judged 
because it does not provide enough information 
on the control medications, exposure duration, 
standardization methods, and other issues.
Although my letter advises that oral bisphos-
phonates not be used in patients with Barrett’s 
esophagus, there are insufficient data at this time 
to recommend screening asymptomatic patients 
for Barrett’s esophagus before the initiation of 
therapy with oral bisphosphonates.
Finally, in considering the risks and benefits of 
therapy for osteoporosis, I note that a recent re-
view article concluded that the efficacy of oral 
bisphosphonates in reducing nonvertebral and hip 
fractures in high-risk elderly women (≥75 years) 
has not been demonstrated.5
Diane K. Wysowski, Ph.D.
Food and Drug Administration 
Silver Spring, MD 20993 
diane.wysowski@fda.hhs.gov
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The New England Journal of Medicine 
Downloaded from nejm.org on January 14, 2017. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 360;17 nejm.org april 23, 20091792
McAdams M, Staffa J, Dal Pan G. Estimating the extent of 1. 
reporting to FDA: a case study of statin-associated rhabdomyoly-
sis. Pharmacoepidemiol Drug Saf 2008;17:229-39.
Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu T-T. 2. 
Alendronate-associated esophageal injury: pathologic and endo-
scopic features. Mod Pathol 1999;12:1152-7.
Ribeiro A, DeVault KR, Wolfe JT III, Stark ME. Alendronate-3. 
associated esophagitis: endoscopic and pathologic features. 
Gastrointest Endosc 1998;47:525-8.
Singh SP, Odze RD. Multinucleated epithelial giant cell 4. 
changes in esophagitis: a clinicopathologic study of 14 cases. 
Am J Surg Pathol 1998;22:93-9.
Inderjeeth CA, Foo AC, Lui MM, Glendenning P. Efficacy and 5. 
safety of pharmacological agents in managing osteoporosis in 
the old old: review of the evidence. Bone 2008 December 16 
(Epub ahead of print).
Mutations in a Thiamine-Transporter Gene  
and Wernicke’s-like Encephalopathy
To the Editor: We report on two previously 
healthy Japanese brothers with a newly discovered 
recessively inherited syndrome similar to Wer-
nicke’s encephalopathy that developed in the sec-
ond decade of life; this syndrome was manifested 
clinically as thiamine-responsive diplopia and 
ptosis without serum thiamine deficiency. The 
patients had complex partial seizures resulting 
in status epilepticus. The administration of high-
dose thiamine (up to 600 mg) improved the sei-
zures within 24 hours, although the ophthalmo-
plegia, nystagmus, and ataxia continued for 
several weeks. There were no extrapyramidal fea-
tures. Magnetic resonance imaging (MRI) of the 
brain showed high-intensity signals in the bilat-
eral medial thalamus and periaqueductal region 
on fluid-attenuated inversion recovery images 
(Fig. 1A); these signals were characteristic of 
findings in Wernicke’s encephalopathy and be-
came normal within 1 month after treatment. 
Interviews of the patients’ relatives confirmed 
that there was no consanguinity in their parents. 
Subacute ophthalmoplegia with nystagmus and 
ataxia occurred repeatedly within several months 
after the discontinuation of 100 mg of thiamine 
per day. There was no history of chronic alcohol-
ism in either patient. Korsakoff’s psychosis did 
not occur even after long periods of Wernicke’s-
like symptoms.
The clinical and imaging features resembling 
Wernicke’s encephalopathy in these patients sug-
gested that the syndrome was caused by a ge-
netic disorder of thiamine metabolism.1 Genomic 
analysis of SLC19A3 encoding human thiamine 
transporter 2 (hTHTR2)2,3 revealed that the pa-
tients were compound heterozygotes for the K44E 
and E320Q mutations; these mutations were not 
present among 192 ethnically matched control 
subjects (Fig. 1B and 1C). Gene-expression analy-
ses of mammalian culture cells showed the ma-
jority of the K44E mutant to be impaired in intra-
cellular transport while remaining normal in the 
endoplasmic reticulum. The E320Q mutant was 
identical in cell-surface localization to the wild-
type protein (Fig. 1D), whereas intracellular thia-
mine uptake activity was decreased significantly 
(Fig. 1E). High expression of SLC19A3 RNA in the 
thalamus (Fig. 1F) may explain the selective tha-
lamic lesions on MRI.
Mutation of SLC19A3 causes a biotin-responsive 
basal-ganglia disease characterized by subacute 
encephalopathy with rigidity and dystonia. Biotin 
is effective and thiamine is ineffective in treat-
ing this childhood-onset disease.4,5 The features 
of this process on MRI are bilateral necrotic le-
sions in the caudate heads; this is markedly dif-
ferent from the locus of lesions in the disease we 
describe.4 The absence of serum thiamine defi-
ciency and the efficacy of high-dose thiamine in 
our patients suggest that dysfunction of hTHTR2 
may induce the expression of another human thia-
mine transporter 1–encoded gene called SLC19A2, 
thereby increasing intracellular thiamine trans-
port in enterocytes and neuronal cells. The iden-
tification of this syndrome provides insight into 
the thiamine metabolism associated with Wer-
nicke’s encephalopathy in humans and suggests 
that the mechanism of Korsakoff’s psychosis may 
be independent of these thiamine pathways.
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